JP5411847B2 - Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 - Google Patents

Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 Download PDF

Info

Publication number
JP5411847B2
JP5411847B2 JP2010506227A JP2010506227A JP5411847B2 JP 5411847 B2 JP5411847 B2 JP 5411847B2 JP 2010506227 A JP2010506227 A JP 2010506227A JP 2010506227 A JP2010506227 A JP 2010506227A JP 5411847 B2 JP5411847 B2 JP 5411847B2
Authority
JP
Japan
Prior art keywords
anticancer
compound
cancer
salt
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010506227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525057A5 (enExample
JP2010525057A (ja
Inventor
雅史 川崎
裕夫 水野
俊浩 坂本
公正 鈴木
マキューン，アーリーン，イー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Priority to JP2010506227A priority Critical patent/JP5411847B2/ja
Publication of JP2010525057A publication Critical patent/JP2010525057A/ja
Publication of JP2010525057A5 publication Critical patent/JP2010525057A5/ja
Application granted granted Critical
Publication of JP5411847B2 publication Critical patent/JP5411847B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010506227A 2007-04-25 2008-04-22 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 Active JP5411847B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010506227A JP5411847B2 (ja) 2007-04-25 2008-04-22 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2007115448 2007-04-25
JP2007115448 2007-04-25
US18507P 2007-10-24 2007-10-24
US61/000,185 2007-10-24
JP2010506227A JP5411847B2 (ja) 2007-04-25 2008-04-22 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
PCT/US2008/005155 WO2008133866A1 (en) 2007-04-25 2008-04-22 Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor

Publications (3)

Publication Number Publication Date
JP2010525057A JP2010525057A (ja) 2010-07-22
JP2010525057A5 JP2010525057A5 (enExample) 2011-06-30
JP5411847B2 true JP5411847B2 (ja) 2014-02-12

Family

ID=39579886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506227A Active JP5411847B2 (ja) 2007-04-25 2008-04-22 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形

Country Status (4)

Country Link
US (1) US8198281B2 (enExample)
EP (1) EP2155752B1 (enExample)
JP (1) JP5411847B2 (enExample)
WO (1) WO2008133866A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2477628T3 (pl) 2009-09-15 2015-02-27 Merck Sharp & Dohme Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu
CN102311443B (zh) * 2011-08-24 2014-07-16 上海北卡医药技术有限公司 盐酸伊立替康的新晶型及其制备方法
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
ME02925B (me) * 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
JP2015214524A (ja) * 2014-05-13 2015-12-03 国立大学法人鳥取大学 増感剤、抗がん剤、および超音波を用いたがん治療
ES2851499T3 (es) * 2015-12-30 2021-09-07 Synthon Bv Proceso para fabricar una forma cristalina de gefitinib
EP3411039B1 (en) * 2016-02-02 2020-06-24 The Regents of The University of Michigan Mercaptopurine hemihydrate
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
WO2018133829A1 (zh) 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
JP7290638B2 (ja) 2017-11-01 2023-06-13 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ｗｅｅ１阻害剤としての大環状化合物及びその使用
WO2019165204A1 (en) 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
US12318452B2 (en) 2018-09-27 2025-06-03 Dana-Farber Cancer Institute, Inc. Degraders of WEE1 kinase
EP3875460A4 (en) 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF
CN113614087B (zh) * 2019-03-22 2023-06-02 首药控股(北京)股份有限公司 Wee1抑制剂及其制备和用途
PT3964510T (pt) 2019-04-30 2024-07-29 Wuxi Biocity Biopharmaceutics Co Ltd Forma cristalina do composto inibidor de wee1 e sua utilização
MX2022004934A (es) 2019-10-25 2022-05-16 Astrazeneca Ab Metodos para tratar un cancer.
KR20220119428A (ko) * 2019-12-20 2022-08-29 리커리엄 아이피 홀딩스, 엘엘씨 복합제
MX2022007625A (es) * 2019-12-20 2022-08-16 Recurium Ip Holdings Llc Combinaciones.
WO2021254389A1 (zh) 2020-06-17 2021-12-23 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物
US20240208982A1 (en) * 2021-03-26 2024-06-27 Orphagen Pharmaceuticals, Inc. Pyrazolopyrimidinone compounds
KR20240004539A (ko) 2021-04-30 2024-01-11 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010617A (es) * 2002-04-26 2004-12-13 Warner Lambert Co Inhibidores de quinasa de puntos de control (wee1 y chk1).
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
EP2155752B1 (en) 2018-09-19
EP2155752A1 (en) 2010-02-24
WO2008133866A1 (en) 2008-11-06
US20100124544A1 (en) 2010-05-20
JP2010525057A (ja) 2010-07-22
US8198281B2 (en) 2012-06-12

Similar Documents

Publication Publication Date Title
JP5411847B2 (ja) Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
US8507504B2 (en) Process for producing bicycloaniline derivatives
EP2016080B1 (en) Dihydropyrazolopyrimidinone derivatives
EP2213673B1 (en) Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2168966B1 (en) Bicycloaniline derivative
EP2411010B1 (en) Novel aminopyridine derivatives having aurora a selective inhibitory action
US8263632B2 (en) Aminopyridine derivatives having Aurora A selective inhibitory action
KR20070072562A (ko) 오로라 ａ 선택적 억제 활성을 갖는 신규한 아미노피리딘유도체
US8367690B2 (en) Aminopyridine derivatives having aurora a selective inhibitory action
ES2702698T3 (es) Polimorfo del derivado de dihidropirazolopirimidinona como inhibidor de la cinasa Wee1

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20110107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110418

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120221

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120321

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130517

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130920

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131108

R150 Certificate of patent or registration of utility model

Ref document number: 5411847

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250